Azilsartan Improves Glycemic Status and Reduces Kidney Damage in Zucker Diabetic Fatty Rats

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F14%3A00431312" target="_blank" >RIV/67985823:_____/14:00431312 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1093/ajh/hpu016" target="_blank" >http://dx.doi.org/10.1093/ajh/hpu016</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/ajh/hpu016" target="_blank" >10.1093/ajh/hpu016</a>

Result language
angličtina
Original language name
Azilsartan Improves Glycemic Status and Reduces Kidney Damage in Zucker Diabetic Fatty Rats
Original language description
The efficacy of azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, to ameliorate metabolic syndrome and kidney damage associated with type 2 diabetes was investigated using Zucker diabetic fatty (ZDF) rats. AZL-M treatment decreased bloodpressure, reduced renal damage, oxidative stress and inflammation in ZDF rats. This data demonstrated that anti-inflammatory and anti-oxidative activities of AZL-M contribute to its kidney protective action
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Project
<a href="/en/project/GA13-10267S" target="_blank" >GA13-10267S: Cardiac ischemic tolerance of spontaneously hypertensive rats: involvement of mitochondrial genome</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)